Noopept (GVS-111)
Cognitive · Peptide-like
Tier C+
Bottom line
Read Off Label grades Noopept (GVS-111) as C+ (5.7/10) based on weak evidence, variable benefit magnitude, and a low-risk safety profile.
Developed at Zakusov Institute.
Studied, labeled, or reported-use context: 10-30 mg PO or sublingual daily — Rx in Russia; research chem elsewhere; not individualized guidance.
Frontier potential — editorial judgment, not evidence
This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.
What the ceiling rests on
A dipeptide with a proposed BDNF and NGF-mediated mechanism, animal data on memory consolidation, and Russian clinical use — active at far lower doses than the racetams it is grouped with.
Why it may not get there
Human evidence is limited to small Russian studies, mostly in cognitive impairment rather than healthy users. No Western trial exists. Reported effects in healthy adults are largely self-reported and would be indistinguishable from expectancy in an unblinded setting.
What would change this A placebo-controlled trial in healthy adults.
What the evidence says
Developed at Zakusov Institute. ~1000x more potent than piracetam by weight. Common in nootropic stacks. Sublingual absorption well-reported. Anxiolytic effect distinguishes from other racetam-likes.
Mechanism
Proline-containing dipeptide structurally similar to piracetam; increases BDNF and NGF; cycloprolylglycine metabolite with anxiolytic activity
Studied, labeled, or reported dose & route
10-30 mg PO or sublingual daily
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Noopept (GVS-111)'s effects?
- Read Off Label rates the evidence for Noopept (GVS-111) as Weak and the benefit magnitude as variable, producing an overall grade of C+ (5.7/10). Developed at Zakusov Institute.
- What safety findings are reported for Noopept (GVS-111)?
- Noopept (GVS-111) has a low risk profile in the database. Low (Russian data); unknown long-term Legal status: Rx in Russia; research chem elsewhere.
- What doses or routes are reported for Noopept (GVS-111)?
- 10-30 mg PO or sublingual daily This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Noopept (GVS-111) work?
- Proline-containing dipeptide structurally similar to piracetam; increases BDNF and NGF; cycloprolylglycine metabolite with anxiolytic activity
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.